| Literature DB >> 35986059 |
Axel Wismüller1,2,3,4, Adora M DSouza3, Anas Z Abidin2, M Ali Vosoughi3, Christopher Gange5, Isabel O Cortopassi6, Gracijela Bozovic7, Alexander A Bankier7, Kiran Batra8, Yosef Chodakiewitz9, Yin Xi8, Christopher T Whitlow10, Janardhana Ponnatapura10, Gary J Wendt11, Eric P Weinberg1, Larry Stockmaster1, David A Shrier1, Min Chul Shin12, Roshan Modi12, Hao Steven Lo7, Seth Kligerman13, Aws Hamid14, Lewis D Hahn13, Glenn M Garcia15, Jonathan H Chung16, Talissa Altes17, Suhny Abbara8, Anna S Bader18.
Abstract
We introduce a multi-institutional data harvesting (MIDH) method for longitudinal observation of medical imaging utilization and reporting. By tracking both large-scale utilization and clinical imaging results data, the MIDH approach is targeted at measuring surrogates for important disease-related observational quantities over time. To quantitatively investigate its clinical applicability, we performed a retrospective multi-institutional study encompassing 13 healthcare systems throughout the United States before and after the 2020 COVID-19 pandemic. Using repurposed software infrastructure of a commercial AI-based image analysis service, we harvested data on medical imaging service requests and radiology reports for 40,037 computed tomography pulmonary angiograms (CTPA) to evaluate for pulmonary embolism (PE). Specifically, we compared two 70-day observational periods, namely (i) a pre-pandemic control period from 11/25/2019 through 2/2/2020, and (ii) a period during the early COVID-19 pandemic from 3/8/2020 through 5/16/2020. Natural language processing (NLP) on final radiology reports served as the ground truth for identifying positive PE cases, where we found an NLP accuracy of 98% for classifying radiology reports as positive or negative for PE based on a manual review of 2,400 radiology reports. Fewer CTPA exams were performed during the early COVID-19 pandemic than during the pre-pandemic period (9806 vs. 12,106). However, the PE positivity rate was significantly higher (11.6 vs. 9.9%, p < 10-4) with an excess of 92 PE cases during the early COVID-19 outbreak, i.e., ~1.3 daily PE cases more than statistically expected. Our results suggest that MIDH can contribute value as an exploratory tool, aiming at a better understanding of pandemic-related effects on healthcare.Entities:
Year: 2022 PMID: 35986059 PMCID: PMC9388980 DOI: 10.1038/s41746-022-00653-2
Source DB: PubMed Journal: NPJ Digit Med ISSN: 2398-6352
Patient demographics.
| Pre-COVID ( | Early COVID ( | Overall ( | ||
|---|---|---|---|---|
| Age, years, median (IQR)* | 60 (46–71) | 58 (43–69) | 59 (45–70) | <0.0001 |
| Female, | 6914 (57.1) | 5335 (54.4) | 12,249 (55.9) | <0.001 |
| Patient location, | <0.001 | |||
| Emergency Department | 7082 (58.5) | 5718 (58.3) | 12,800 (58.4) | |
| Inpatient | 3298 (27.2) | 2844 (29.0) | 6142 (28.0) | |
| Outpatient | 1300 (10.7) | 904 (9.2) | 2204 (10.0) |
*Only patients with known age greater than or equal to 18 years are included in this analysis.
Fig. 1Weekly CTPA exams performed.
Total weekly number of CTPA exams performed at each institution (a) and across all of the institutions combined (b), demonstrating an overall decrease in the early pandemic period (red), compared to the pre-pandemic period (green).
CTPA results during the two observation periods.
| Exam Result | Pre-COVID | Early COVID | Total |
|---|---|---|---|
| PE+ | 1200 (9.9%) [1292] | 1138 (11.6%) [1046] | 2338 |
| PE− | 10,906 (90.1%) [10814] | 8668 (88.4%) [8760] | 19,574 |
| Total | 12,106 | 9806 | 21,912 |
A positive PE result was more likely during the early COVID period compared to before the pandemic. The contingency table provides the following information: the observed cell totals, column percentages in parentheses, and the expected cell totals in brackets.
Fig. 2Total acquired CTPA scans and PE positivity rates.
Total numbers of acquired CTPA scans (a) during the two observation periods demonstrate a clear decrease in the total number of studies performed. Simultaneously, the prevalence of positive PE cases (blue bar) increased in the early COVID-19 period (b). For a detailed account of institution-specific data, please see Supplementary Fig. 3 of the Supplemental Material.
Fig. 3Changes in CTPA utilization and PE positivity rate over time.
Superimposed results demonstrate a drop in the centered 3-week moving average of weekly total CTPA exams performed (orange curve) with a simultaneous increase in PE positivity rates (blue curve).
Fig. 4PE positivity and prevalence.
Adjusted odds ratios for PE positivity (a), with the pre-COVID-19 period as the reference standard, and adjusted marginal estimate for PE prevalence by each site as well as combined (b). The sizes of the bubbles are proportional to 1/SE of the % estimates.
A natural language processing (NLP) validation trial using a manual review of 2400 radiology reports was conducted at 12 participating institutions.
| Manual classification | |||
|---|---|---|---|
| NLP classification | PE− | PE+ | Total |
| PE− | 1198 | 11 | 1200 |
| PE+ | 38 | 1162 | 1200 |
| Total | 1227 | 1173 | 2400 |
Results demonstrate an overall accuracy of 98%.
Fig. 5Geographic distribution of the participating institutions.
CCHS Christiana Care Health System, CSMC Cedars-Sinai Medical Center, PHHS Parkland Health and Hospital System, UCM University of Chicago, UCSD University of California, San Diego, UMASS University of Massachusetts, UMHC University of Missouri-Columbia, UOWI University of Wisconsin-Madison, URMC University of Rochester Medical Center, UTMB University of Texas-Medical Branch, UTSW University of Texas-Southwestern, WF Wake Forest School of Medicine. The size of the circle is proportional to the number of cases contributed to this study by that institution. The detailed information by the site is available online (https://www.aidoc.com/resources/research/). Base map © OpenStreetMap (https://www.openstreetmap.org/copyright).
Inclusion criteria for CTPA studies at each institution.
| Institution | Inclusion criteria |
|---|---|
| 1. CCHS | Any study description that included “PE” |
| 2. CSMC | Any protocol name that included “PE”/“P.E”/“Pulmonary embolism” |
| 3. PHHS | Any study description that included “Angio* Chest” |
| 4. UCM | Any study description that included “PE”/“Pulmonary embolism” |
| 5. UCSD | All cases with the study description “CTA PULMONARY EMBOLUS” |
| 6. UMass | Any procedure description that included “PE”/“Pulmonary emb”/“ CT ANGIOGRAM CHEST W” |
| 7. UMHC | Any study description that included “PE”/“CT pulmonary angiogram” |
| 8. URMC | All cases with the procedure description “CT ANGIO CHEST” |
| 9. UTMB | Any procedure description that included “PE”/“Pulmonary emb”/“Angio* Chest” |
| 10. UTSW | Any study description that included “Angio* Chest” |
| 11. UOWI | Any procedure description that included “PE”/“P.E.”/“Pulmonary emb”/“Angio* Chest”/“CTA CHEST” |
| 12. Wake Forest | Any procedure description that included “PE” |
| 13. Yale | Any study description that included “PE”/“Pulmonary emb” |
Individual institutional review board study numbers.
| Institution name | IRB study identification |
|---|---|
| UCM | IRB19-0804-CR001 |
| CCHS | 40109 |
| UTSW | STU-2020-0818 |
| Yale | 2000027425 |
| UMHC | 2017710 |
| CSMC | STUDY00000897 |
| UCSD | 201436 |
| UMass | H00020868 |
| Wake Forest | IRB00068157 |
| PHHS | STU-2020-0818 |
| UTMB | 20-0176 |
| URMC | STUDY00005185 |
| UOWI | 2016-0418 |